Apexium Financial LP Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Apexium Financial LP grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 108.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,679 shares of the company's stock after purchasing an additional 11,262 shares during the quarter. Apexium Financial LP's holdings in Johnson & Johnson were worth $3,135,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in JNJ. Vinva Investment Management Ltd boosted its stake in Johnson & Johnson by 6.8% in the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock worth $17,988,000 after purchasing an additional 7,110 shares during the period. Financial Counselors Inc. grew its stake in Johnson & Johnson by 5.3% during the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock valued at $29,996,000 after acquiring an additional 9,309 shares in the last quarter. Meridian Investment Counsel Inc. increased its holdings in Johnson & Johnson by 19.6% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock valued at $3,667,000 after acquiring an additional 3,710 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock valued at $2,858,543,000 after purchasing an additional 102,502 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new position in shares of Johnson & Johnson during the third quarter valued at about $69,859,000. Institutional investors own 69.55% of the company's stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on JNJ shares. Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Stifel Nicolaus cut their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $170.44.

Johnson & Johnson Stock Up 1.9 %

Shares of JNJ stock traded up $2.87 on Thursday, hitting $154.02. The stock had a trading volume of 4,064,280 shares, compared to its average volume of 9,429,284. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The business has a 50 day moving average price of $147.73 and a 200 day moving average price of $156.10. The company has a market cap of $370.81 billion, a PE ratio of 23.16, a P/E/G ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company's quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $2.29 earnings per share. Research analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.22%. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.